Clene Inc. (CLNN) vs INmune Bio, Inc. (INMB)
Clene Inc. and INmune Bio, Inc. are both Biotechnology companies. Clene Inc. and INmune Bio, Inc. are of similar size ($59.8M and $55.5M). Clene Inc. grew revenue faster over the last twelve months: −31.1% against −51.6%. INmune Bio, Inc. has the higher net margin (0.00% vs −20,059.9%) and the lower return on invested capital (−646.9% vs 0.00%). Across the 17 metrics below, INmune Bio, Inc. leads on 9 and Clene Inc. on 8.
Valuation
Profitability
| Metric | CLNN | INMB | Biotechnology median |
|---|---|---|---|
| Gross margin | 70.05% | 100.00% | 65.16% |
| Operating margin | (10,431.98%) | 0.00% | 0.00% |
| Net margin | (20,059.90%) | 0.00% | 0.00% |
| Free cash flow margin | (8,095.43%) | 0.00% | 0.00% |
| Return on equity | 237.15% | (74.82%) | (57.72%) |
| Return on assets | (174.99%) | (57.08%) | (49.22%) |
| Return on invested capital | 0.00% | (646.94%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack